TY  - JOUR
AU  - Berger, Anne Katrin
AU  - Lücke, Stephan
AU  - Abel, Ulrich
AU  - Haag, Georg Martin
AU  - Grüllich, Carsten
AU  - Stange, Annika
AU  - Dietrich, Mareike
AU  - Apostolidis, Leonidas
AU  - Freitag, Angelika
AU  - Trierweiler, Claudia
AU  - von Gall, Carl
AU  - Ose, Jennifer
AU  - Giesel, Frederik
AU  - Weber, Tim Frederik
AU  - Lordick, Florian
AU  - Haberkorn, Uwe
AU  - Jäger, Dirk
TI  - Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
JO  - British journal of cancer
VL  - 119
IS  - 2
SN  - 1532-1827
CY  - Edinburgh
PB  - Nature Publ. Group
M1  - DKFZ-2018-01129
SP  - 170 - 175
PY  - 2018
AB  - To assess the predictive value of early metabolic response (ΔSUV) after short-term treatment with first-line cetuximab in patients (pts) with RAS-wt metastatic colorectal cancer (mCRC).In this prospective phase II study, RAS-wt mCRC pts received a single-agent cetuximab run-in therapy of 2 weeks. ΔSUV was assessed with FDG-PET/CT on days 0 and 14. Early clinical response (ECR) was evaluated with CT on day 56 after treatment with FOLFIRI-cetuximab. Primary endpoint was the predictive significance of ΔSUV for ECR. Secondary endpoints were PFS (progression free survival), OS and the influence of ΔSUV on survival.Forty pts were enroled and 33 pts were evaluable for the primary endpoint. The CT response rate was 57.6
LB  - PUB:(DE-HGF)16
C6  - pmid:29961759
DO  - DOI:10.1038/s41416-018-0152-4
UR  - https://inrepo02.dkfz.de/record/136660
ER  -